Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

Inclusion Criteria: * Patient is 50 years or older * Patient is willing to participate in this study and to follow the criteria and protocol of this study. * Patient is not involved with another clinical trial. * Ability to understand the informed consent and willingness to sign the consent. * Presence of a submacular vascularized or fibrovascular PED. Central foveal involvement by the PED or the CNV due to age related macular degeneration. * PED less than or equal to 12 disc area in size * BCVA with ETDRS of greater than or equal to 19 letters and less than or equal to 69 letters (20/400 to 20/40) * Central 1-mm foveal thickness of greater than or equal to 250 microns on OCT. * Greatest linear diameter of the submacular hemorrhage needs to be less than 50% of the entire PED. * Submacular fibrosis needs to be less than 50% of the entire PED. * Sufficiently clear media (cornea, anterior chamber, lens, vitreous) for OCT, FA, and FP. * Intraocular pressure of 25 mm or less in the study eye, with or without use of ocular hypotensive agents. Exclusion Criteria: * Pregnancy or lactation * Premenopausal women not using adequate contraception * Known serious allergies to ranibizumab, fluorescein dye, drug for pupillary dilation, topical anesthetic, sterilizing solution * Contraindication to pupillary dilation in study eye * Any condition (including inability to read visual acuity charts or language barrier) that may preclude patient's ability to comply with the study protocol requ…